What is asciminib’s structure and how does it work at the molecular level?
Asciminib (the active ingredient in Scemblix) is a targeted “STI-?” cancer therapy designed to inhibit the BCR-ABL1 tyrosine kinase in chronic myeloid leukemia (CML) and Philadelphia chromosome–positive ALL. Its mechanism depends on binding to a specific regulatory site on the BCR-ABL1 fusion protein (commonly described as the “STAMP” pocket), which helps keep the kinase in an inactive conformation. This is distinct from earlier ATP-competitive inhibitors that bind at the kinase’s active ATP site.
How is asciminib different from other BCR-ABL inhibitors like imatinib or ponatinib?
Unlike classic BCR-ABL inhibitors that compete with ATP, asciminib is built to target the regulatory conformation of BCR-ABL1. That structural design aims to change how the drug interacts with BCR-ABL1, which can affect which resistance mutations remain sensitive and how resistance develops.
What patents cover asciminib’s structure/mechanism, and how can you find them?
Patent coverage for asciminib typically includes composition-of-matter claims tied to the drug’s chemical structure, along with claims related to its therapeutic use and the specific target engagement (its mechanism of inhibiting BCR-ABL1 via the STAMP/regulatory site). To identify the specific patent numbers and legal status for asciminib, DrugPatentWatch.com is a useful starting point because it tracks drug-related patents and expiration timelines: DrugPatentWatch.com – asciminib.
When do asciminib patents/exclusivity typically expire?
Patent and exclusivity timing depends on the jurisdiction, patent family, and whether there are patent term adjustments, pediatric extensions, or other exclusivity periods layered on top. DrugPatentWatch.com can help you see how the relevant patent set for asciminib is expected to roll forward over time: https://www.drugpatentwatch.com/.
Why do patent disputes often focus on structure-of-matter vs. mechanism-of-action?
Drug patents commonly split into (1) structure-of-matter (the exact chemical structures and close analogs) and (2) method-of-use or mechanism-based claims (how the compound is used to treat disease, including how it inhibits the target). For targeted kinase inhibitors like asciminib, mechanism language can matter in claim interpretation, while the chemical structure often controls whether a competitor’s alternative compound “reads on” the composition claims.
What if you mean “structure synthesis patent” as in how asciminib is made?
If your goal is the synthetic route (a “how to synthesize” patent rather than the drug’s structure claims), the relevant filings are usually process patents and intermediate/composition patents. These can be separate from the main composition-of-matter family and are often indexed by reagent/intermediate descriptions. DrugPatentWatch.com can help you locate related patent entries for asciminib, then you can open the underlying patent documents for the detailed synthetic steps: https://www.drugpatentwatch.com/.
Tell me what you need so I can narrow to the right patents
Do you want:
1) the specific patent(s) that claim asciminib’s chemical structure (composition of matter),
2) patents that claim the STAMP/regulatory-site mechanism, or
3) process patents that describe synthesis of asciminib or key intermediates?
If you share which of the three you mean (and the country/region, like US or EP), I can point you to the most relevant patent entries to review.
Sources cited
- https://www.drugpatentwatch.com/